	Application No.	Applicant(s)
Aladiaa af Allawat 1114	10/606,608	HAYES ET AL.
Notice of Allowability	Examiner	Art Unit
	Kagnew H. Gebreyesus	1652
The MAILING DATE of this communication appeal all claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this apport or other appropriate communication GHTS. This application is subject to	olication. If not included will be mailed in due course. THIS
1. This communication is responsive to <u>1/12/06</u> .		
2. The allowed claim(s) is/are 1, 2,5-9.		
 Acknowledgment is made of a claim for foreign priority unally all b) Some* c) None of the: Certified copies of the priority documents have Certified copies of the priority documents have Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). 	been received. been received in Application No	
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		complying with the requirements
4. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give	•	
 5. CORRECTED DRAWINGS (as "replacement sheets") muse (a) including changes required by the Notice of Draftspers 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the paper No./Mail Date 	on's Patent Drawing Review (PTO-9 Amendment / Comment or in the O 84(c)) should be written on the drawin	ffice action of gs in the front (not the back) of
 DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT 		
Attachment(s)		
1. Notice of References Cited (PTO-892)		atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ⊠ Interview Summary Paper No./Mail Dat	6. 🗵 Interview Summary (PTO-413), Paper No./Mail Date (しょ) よん
 3. Information Disclosure Statements (PTO-1449 or PTO/SB/08) Paper No./Mail Date 6/26/03 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material 	Paper No./Mail Date 1/29 b 6 7. ⊠ Examiner's Amendment/Comment	
	8. X Examiner's Stateme	nt of Reasons for Allowance
	9. Other	

Application/Control Number: 10/606,608

Art Unit: 1652

DETAILED ACTION

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Barry Swanson on January 30, 2006 and further on February 6th, 2006.

The application has been amended as follows:

Specification:

The first line of the specification regarding the "Cross Reference to Related Applications" must be updated and corrected as follows:

"This Application is a Divisional of Application Serial No. 10/324,981, filed 20, December 2002, currently abandoned, which is a Continuation of Application Serial No. 10/117,166, filed 05 April 2002, now abandoned, which is a Continuation of Application Serial No. 09/963,266, filed 26 September 2001, now abandoned which is a continuation of Application Serial No. 09/489,650, filed 24 January 2000, now abandoned."

Claim 2(i) on line 3 delete: -- or a fragment thereof having at least 15 nucleotides --

Claim 2((k) replace: -- "polynucleotides of (a) – (k)" – with – "polynucleotides of (a) – (j)"--.

Claim 6 on line 3 replace: -- "a cell" – with -- an isolated host cell --

Claim 7 replace: "A recombinant" - with—"The recombinant".

Claim 9 on line 1 replace: "a host cell" – with – "the host cell".

Cancel claims 3 and 4.

Application/Control Number: 10/606,608

Art Unit: 1652

2. The following is an examiner's statement of reasons for allowance: The isolated polynucleotide sequence of SEQ ID NO: 1 encoding the specific polypeptide of SEQ ID NO: 2 and polynucleotide and polypeptide sequences having at least 95% identity to SEQ ID NO: 1 and 2 respectively and having methionyl tRNA synthetase activity have not been described in the prior art. The closest prior art disclosure is by Ruben et al who disclose a sequence having 95.4% sequence identity to a portion of SEQ ID NO: 1 encompassing nucleotide 695 to 1061. However the full-length sequence disclosed by Ruben et al does not show a significant similarity to the sequence disclosed by applicants.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kagnew H. Gebreyesus whose telephone number is 571-272-2937. The examiner can normally be reached on 8:30am-5: 30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Achutamurthy ponnathapura can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/606,608

Art Unit: 1652

. . .

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Kagnew Gebreyesus PhD:

PRIMARY EXAMINER

1600

Page 4